Aprepitant, Palonosetron and Dexamethasone Antiemetic Therapy Evaluation trial in germ cell tumor (APDATE)

Aprepitant, Palonosetron and Dexamethasone Antiemetic Therapy Evaluation trial in germ cell tumor (APDATE) - Antiemetic therapy in germ cell tumor

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000008110

Enrollment

Registered

2012-06-05

Start date

2012-06-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Germ cell tumor

Interventions

Aprepitant, palonosetron and dexamethasone

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: 1. Germ cell tumor 2. Receiving BLM/ETP/CDDP chemotherapy 3. No history of systemic chemotherapy 4. Sufficient organ functions 5. Ability of oral intake 6. ECOG PS 0-2 7. Informed consent

Exclusion criteria

Exclusion criteria: 1. Uncontrollable complications 2. Brain metastasis 3. Active convulsive disease 4. Plural effusion or ascites requiring puncture 5. Obstruction of the gastric outlet or ileus 6. Vomiting or severe nausea before the chemotherapy 7. Anaphylaxis against 5-HT3 receptor inhibitors, aprepitant or dexamethasone 8. Disapproval of contraception 9. History og aprepitant or palonostron 10. Participation of other clinical trials of antiemetics

Design outcomes

Primary

Measure	Time frame
Complete response	—

Secondary

Measure	Time frame
Conplete control (no emetic episodes, no rescue medication use and no more than mild nausea), adverse events	—

Countries

Japan

Contacts

Public ContactFumimasa Fukuta

Sapporo Medical University School of Medicine Department of Urology

uroikai@sapmed.ac.jp81-11-611-2111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026